Document:

Exhibit 10.1

 

FORM OF TENDER AND SUPPORT AGREEMENT

 

This
Tender and Support Agreement (this “Agreement”) is entered into as of February 14, 2022, by and among Collegium
Pharmaceutical, Inc., a Virginia corporation (“Parent”), Bristol Acquisition Company Inc., a Delaware corporation and
a wholly owned subsidiary of Parent (“Purchaser”), and each of the Persons set forth on Schedule A hereto (each
a “Stockholder”).

 

Recitals

 

A.           Parent,
Purchaser and BioDelivery Sciences International, Inc. (the “Company”) are entering into an Agreement and Plan of Merger,
dated as of the date hereof (the “Merger Agreement”), which provides, among other things, for (i) Purchaser to commence
a cash tender offer (the “Offer”) to acquire all of the outstanding shares of Company Common Stock, par value $0.001
per share, of the Company (the “Common Shares”) and (ii) following the consummation of the Offer, the merger of Purchaser
with and into the Company, with the Company continuing as the Surviving Corporation and as a wholly owned subsidiary of Parent (the “Merger”),
upon the terms and subject to the conditions set forth in the Merger Agreement.

 

B.           Stockholder
is, as of the date hereof, the record and “beneficial owner” (within the meaning of Rule 13d-3 under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”)) of certain Common Shares set forth opposite the name of the Stockholder
on Schedule A hereto.

 

C.           As
a condition to the willingness of Parent and Purchaser to enter into the Merger Agreement and as an inducement in consideration therefor,
Stockholder has agreed to enter into this Agreement and tender and vote Stockholder’s Subject Securities (as defined below) as described
herein.

 

AGREEMENT

 

In consideration of the foregoing,
and the mutual covenants and agreements set forth in the Merger Agreement and as an inducement and in consideration therefor, the parties
to this Agreement, intending to be legally bound, agree as follows:

 

 SECTION 1.          CERTAIN DEFINITIONS

 

For purposes of this Agreement:

 

(a)               
Capitalized terms used but not defined herein shall have the respective meanings assigned to those terms in the Merger Agreement.

 

(b)               
“Expiration Date” means the earliest to occur, without any notice or other action by any Person, of (i) the
valid termination of the Merger Agreement in accordance with its terms,(ii) the Effective Time, (iii) the date of any material modification,
waiver or amendment to any provision of the Merger Agreement without Stockholder’s consent that reduces the amount or changes the
form of consideration payable to the Stockholder pursuant to the Merger Agreement as in effect on the date hereof or (iv) the mutual written
consent of each of Parent, Purchaser and the Stockholder.

 

(c)               
Stockholder is deemed to “Own” or to have acquired “Ownership” of a security if Stockholder
(i) is the record owner of such security; or (ii) is the “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange
Act) of such security.

 

     

     

    

 

(d)               
 “Subject Securities” means (i) all Common Shares Owned by Stockholder as of the date hereof and (ii) all additional
Common Shares of which Stockholder acquires ownership during the Support Period (including any Common Shares issuable upon the exercise
of any Company Warrant). For the avoidance of doubt, Company Options and Company RSUs beneficially owned by Stockholder shall not be considered
Subject Securities, and Common Shares issued upon the exercise of a Company Option or the settlement of a Company RSU during the Support
Period shall be Subject Securities.

 

(e)               
“Support Period” means the period commencing on (and including) the date of this Agreement and ending on (and
including) the Expiration Date.

 

(f)                
A Person is deemed to have effected a “Transfer” of a security if such Person directly or indirectly: (i) sells,
transfers, pledges, gifts, hedges, encumbers, assigns, distributes, grants a Lien on or an option with respect to, enters into any derivative
arrangement with respect thereto, transfers or disposes of such security or any interest in such security or right therein to any Person
other than Parent or Purchaser; (ii) enters into an agreement or commitment contemplating the possible sale of, pledge of, gift, hedge,
assignment of, encumbrance or Lien of, grant of an option with respect to, a derivative arrangement, transfer of or disposition of such
security or any interest or right therein to any Person other than Parent or Purchaser; or (iii) reduces such Person’s beneficial
ownership of or interest in or risk relating to such security or enters into a derivative arrangement with respect to such security.

 

 SECTION 2.          TRANSFER OF SUBJECT SECURITIES AND VOTING RIGHTS

 

2.1          
Restriction on Transfer of Subject Securities. Subject to Section 2.3 below, during the Support Period, Stockholder
shall not cause or permit any Transfer of any of the Subject Securities to be effected. Without limiting the generality of the foregoing,
during the Support Period, Stockholder shall not tender, agree to tender or permit to be tendered any of the Subject Securities in response
to or otherwise in connection with any tender or exchange offer other than the Offer.

 

2.2         
Restriction on Transfer of Voting Rights. During the Support Period, Stockholder shall ensure that: (a) none of the Subject
Securities is deposited or otherwise transferred into a voting trust or any voting agreement or arrangement is entered into with respect
to the Subject Securities (other than this Agreement); (b) no proxy, power-of-attorney, consent right or other authorization is granted,
and no voting agreement or similar agreement is entered into, with respect to any of the Subject Securities (other than this Agreement);
and (c) no action is taken or permitted that would in any way restrict, limit or interfere with the performance of Stockholder’s
obligations hereunder or otherwise make any representation or warranty of Stockholder herein untrue or incorrect.

 

2.3          Permitted
Transfers. Section 2.1 above shall not prohibit a Transfer of Subject Securities by Stockholder: (a) if Stockholder is an
individual (i) to any member of Stockholder’s immediate family, or to a trust for the benefit of Stockholder or any member of
Stockholder’s immediate family, or otherwise for estate planning purposes, or
(ii) by will or under the laws of intestacy upon the death of Stockholder; (b) if such Transfers or dispositions do not involve a
change in beneficial ownership; (c) if Stockholder is a trust, to any beneficiary of Stockholder or the estate of any such
beneficiary; (d) by operation of law or to a charitable organization qualified under Section 501(c)(3) of the Code; (e) by exercise
of a Company Option (including a net or cashless exercise of such Company Option to purchase Common Shares); (f) to the Company to
cover tax withholding obligations of Stockholder in connection with any option exercise or the vesting of any restricted stock or
restricted stock unit award, provided that the underlying Subject Securities shall continue to be subject to the restrictions on
transfer set forth in this Agreement; or (g) if Stockholder is a corporation, limited partnership, partnership or other entity, to
any controlled affiliate of such Stockholder; provided, however, that a Transfer referred to in clauses
 “(a)” through “(d)” and “(g)” of this sentence shall be permitted only if (as
a precondition to such Transfer, the transferee agrees in a written document, reasonably satisfactory in form and substance to
Parent, to be bound by all of the terms of this Agreement.

 

    2

     

    

 

 SECTION 3.        TENDER OF SUBJECT SECURITIES

 

3.1          
Tender of Subject Securities. Until the Expiration Date, Stockholder hereby agrees, subject to Section 3.3 to tender
the Subject Securities free and clear of all Liens, or cause such Subject Securities (collectively, the “Initial Tender Shares”)
to be tendered, into the Offer no later than the tenth (10th) Business Day following the commencement of the Offer within the
meaning of Rule 14d-2 under the Exchange Act (the “Tender Deadline”). If Stockholder acquires additional Subject Securities
after the date hereof and during the Support Period , Stockholder shall tender or cause to be tendered such Subject Securities on or before
the earlier of (a) five (5) Business Days after such acquisition, and (b) one (1) Business Day prior to the Expiration Date (the “Additional
Tender Shares”, and together with the Initial Tender Shares, the “Tender Shares”). Until the Expiration Date,
Stockholder will not withdraw the Tender Shares, or cause the Tender Shares to be withdrawn, from the Offer. Stockholder shall notify
Parent as promptly as reasonably practicable in writing of the number of any additional shares of Common Shares which Stockholder acquires
beneficial or record ownership after the date hereof and during the Support Period.

 

3.2          
Return of Subject Securities. If (a) the Offer is terminated or withdrawn by Parent or Purchaser, or (b) the Expiration Date
occurs prior to the purchase of the Subject Securities in the Offer, Parent and Purchaser shall promptly and in any event no later than
two (2) Business Days direct any depository acting on behalf of Parent and Purchaser to return, all Tender Shares to Stockholder.

 

3.3         
No Requirement to Exercise. Notwithstanding anything in this Agreement to the contrary, nothing herein shall require Stockholder
to exercise any Company Option or other equity award or require any Stockholder to purchase any Common Shares, and nothing herein shall
prohibit Stockholder from exercising any Company Option or other equity award or warrant held by Stockholder in accordance with the applicable
plan, award grant agreement(s), and/or other agreements(s) or document(s) evidencing such Company Option or other equity award or warrant,
as applicable.

 

 SECTION 4.         VOTING OF COMMON SHARES

 

4.1         
Voting Covenant. During the Support Period, Stockholder hereby irrevocably and unconditionally agrees that, at
any annual or special meeting of the stockholders of the Company, however called, including any adjournment or postponement thereof, and
in connection with any action proposed to be taken by written consent of the stockholders of the Company, Stockholder shall, (or shall
cause)in each case to the fullest extent that such Subject Securities are entitled to be voted therein: (a) appear at each such meeting
or otherwise cause all such Subject Securities to be counted as present thereat for purposes of determining a quorum; and (b) be present
(in person or by proxy) and vote (or cause to be voted), or deliver (or cause to be delivered) a written consent with respect to, all
of the Subject Securities, and unless otherwise directed in writing by Parent:

 

(a)               
in favor of (i) the Merger, the execution and delivery by the Company of the Merger Agreement and the adoption and approval of
the Merger Agreement and the terms thereof, and (ii) each of the other Transactions;

 

(b)                against
any action or agreement which is intended or would reasonably be expected to impede, delay, postpone, interfere with, nullify,
prevent or adversely affect in any material respect the Merger, the Offer or any of the other Transactions or this Agreement,
including any Acquisition Proposal of any Person (other than Parent and Purchaser) to acquire the Company or all or substantially
all of the assets thereof and action in furtherance of any Acquisition Proposal or to engage in any other similar extraordinary
corporate transaction; and

 

    3

     

    

 

During the Support Period, Stockholder shall not
enter into any agreement or understanding with any Person to vote or give instructions in a manner inconsistent with clauses “(a)”
or “(b)” of this Section 4.1.

 

4.2          
Further Assurances. Stockholder shall not enter into any tender, voting or other such agreement, or grant a proxy or power
of attorney, with respect to any of the Subject Securities that is inconsistent with this Agreement or otherwise take any other action
with respect to any of the Subject Securities that would restrict, limit or interfere with the performance of any of Stockholder’s
obligations hereunder.

 

 SECTION 5.         WAIVER OF APPRAISAL RIGHTS

 

5.1          
During the term of this Agreement, Stockholder hereby (a) irrevocably and unconditionally waives, and agrees not to exercise
or assert, on its own behalf or on behalf of any other holder of Common Shares, any rights of appraisal, any dissenters’ rights
or any similar rights under Section 262 of the Delaware General Corporation Law (the “DGCL”) relating to the Merger
that Stockholder may have by virtue of, or with respect to, any Subject Securities and (b) agrees not to commence or join in and agrees
to use commercially reasonable efforts to take all actions necessary to opt out of, any class in any class action with respect to, any
claim, derivative or otherwise, against Parent, Purchaser or the Company or any of their respective successors that challenges the validity
of, or seeks to enjoin, any provision of this Agreement or alleges breach or any fiduciary duty of any person in connection with the negotiation
and entry into the Merger Agreement.

 

 SECTION 6.         REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER

 

Stockholder hereby represents
and warrants to each of Parent and Purchaser as follows:

 

6.1          
Authorization, etc. Stockholder has full authority and legal capacity to execute and deliver this Agreement and to perform
Stockholder’s obligations hereunder. This Agreement has been duly authorized, executed and delivered by Stockholder and, assuming
due authorization, execution and delivery by Parent and Purchaser, constitutes a legal, valid and binding obligation of Stockholder, enforceable
against Stockholder in accordance with its terms, except as enforcement thereof may be limited by (i) Laws of general application relating
to bankruptcy, insolvency and the relief of debtors and (ii) rules of law governing specific performance, injunctive relief and other
equitable remedies. If Stockholder is a corporation, then Stockholder is a corporation duly organized, validly existing and in good standing
under the laws of the jurisdiction in which it was organized. If Stockholder is a general or limited partnership, then Stockholder is
a partnership duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was organized. If Stockholder
is married, and any of the Subject Securities constitute community property or otherwise need spousal or other approval for this Agreement
to be legal, valid and binding, this Agreement has been duly executed and delivered by Stockholder’s spouse and, assuming due authorization,
execution and delivery by Parent and Purchaser, is enforceable against Stockholder’s spouse in accordance with its terms, except
as enforcement thereof may be limited by (x) Laws of general application relating to bankruptcy, insolvency and the relief of debtors
and (y) rules of law governing specific performance, injunctive relief and other equitable remedies.

 

    4

     

    

 

6.2          
No Conflicts or Consents.

 

(a)                The
execution and delivery of this Agreement by Stockholder does not, and the performance of this Agreement by Stockholder will not: (a)
assuming the filing of such reports as may be required under Sections 13(d) and 16 of the Exchange Act, which such Stockholder will
file, violate any Law applicable to such Stockholder or such Stockholder’s Shares, (b) except as may be required by applicable
federal securities laws, require any consent, approval, order, authorization, permit or other action by, or filing with or notice
to, any Person (including any Governmental Authority) under, constitute a default (with or without the giving of notice or the lapse
of time or both) under, or give rise to any right of termination, cancellation, modification or acceleration under, or result in the
creation of any Liens on any of the Shares pursuant to, any Contract, trust, Order or other instrument binding on such Stockholder
or such Stockholder’s Shares or any applicable Law; (c) if Stockholder is not an individual, violate, contravene or conflict
with or result in any breach of any provision of the certificate of incorporation or bylaws (or other similar governing documents)
of Stockholder; or (d) result in or constitute (with or without notice or lapse of time) any material breach of or material default
under, or give to any other Person (with or without notice or lapse of time) any right of termination, amendment, acceleration or
cancellation of, or result (with or without notice or lapse of time) in the creation of any Lien on any of the Subject Securities
pursuant to, any Contract to which Stockholder is a party or by which Stockholder or any of Stockholder’s Affiliates or
properties is or may be bound or affected, except, in each case, for any conflict, violation, breach, default or right which would
not adversely affect in any material respect the ability of Stockholder to perform its obligations hereunder.

 

(b)               
The execution and delivery of this Agreement by Stockholder does not, and the performance of this Agreement by Stockholder will
not, require any filing with or notification of, nor any permit, authorization, consent or approval of, any Person, other than under any
applicable Antitrust Laws or where the failure to make such filings or obtain such permits, authorizations, consents or approvals would
not, individually or in the aggregate, prevent or materially delay the performance by Stockholder of any of its obligations under this
Agreement. Assuming the compliance of each of the Company, Parent and Purchaser with all applicable Antitrust Laws, no consent or notification
of, or registration, declaration or filing with, any Governmental Body is required to be obtained or made by or with respect to Stockholder
in connection with the execution, delivery or performance of this Agreement or the consummation of the transactions contemplated hereby,
other than such reports under Sections 13(d) and 16 of the Exchange Act as may be required in connection with this Agreement, or where
the failure to obtain such consents or make such registrations, declarations or filings would not adversely affect in any material respect
the ability of Stockholder to perform its obligations hereunder.

 

6.3          
Title to Common Shares. As of the date hereof, stockholder (a) beneficially owns (as defined in Rule 13d-3 under the Exchange
Act), free and clear of any Lien (other than Liens that would not adversely affect in any material respect the ability of Stockholder
to perform Stockholder’s obligations hereunder), the Subject Securities set forth opposite Stockholder’s name on Schedule
A to this Agreement, and (b) except as set forth in Schedule A hereto, does not hold or have any ownership interest in any
other Common Shares or any performance based stock awards, restricted stock, restricted stock units, options (including any granted pursuant
to the Company Equity Plan) or Company Warrants, or other rights or securities convertible into or exercisable or exchangeable for Common
Shares.

 

6.4          
Legal Proceedings. As of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of Stockholder,
threatened against Stockholder or any of Stockholder's properties or assets that would reasonably be expected to impair the ability of
Stockholder to perform Stockholder’s obligations hereunder.

 

6.5         
Merger Agreement. Stockholder and its Representatives have reviewed and understand the terms of this Agreement and the Merger
Agreement, and Stockholder has had the opportunity to consult with Stockholder’s counsel in connection with this Agreement.

 

    5

     

    

 

6.6          
 Voting Power. Stockholder has full voting
power with respect to all the Subject Securities, and full power of disposition, full power to issue instructions with respect to the
matters set forth herein and full power to agree to all of the matters set forth in this Agreement, in each case with respect to all the
Subject Securities. None of the Subject Securities are subject to any stockholders’ agreement, proxy, voting trust or other agreement
or arrangement with respect to the voting of such Subject Securities, except as provided hereunder.

 

6.7         
Reliance. Stockholder understands and acknowledges that Parent and Purchaser are entering
into the Merger Agreement in reliance upon Stockholder’s execution, delivery and performance of this Agreement.

 

 SECTION 7.          REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER

 

Each of Parent and Purchaser
hereby, jointly and severally, represents and warrants to Stockholder as follows:

 

7.1         
Authorization, etc. Each of Parent and Purchaser has all necessary corporate power and authority to execute and deliver this
Agreement and to perform its obligations hereunder. This Agreement has been duly authorized, executed and delivered by each of Parent
and Purchaser and, assuming due authorization, execution and delivery by Stockholder, constitutes a legal, valid and binding obligation
of Parent and Purchaser, enforceable against Parent and Purchaser in accordance with their terms, subject to (a) Laws of general application
relating to bankruptcy, insolvency and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and
other equitable remedies. Each of Parent and Purchaser is a corporation duly organized, validly existing and in good standing under the
Laws of the jurisdiction in which it was organized, except where the failure to be in good standing would not, individually or in the
aggregate, prevent or materially delay the performance by Parent or Purchaser of their obligations under this Agreement.

 

7.2         
No Conflicts or Consents. The execution and delivery of this Agreement by Parent and Purchaser does not, and the performance
of this Agreement by Parent and Purchaser and their respective Representatives will not: (a) conflict with or violate any Law or Order
applicable to Parent and Purchaser (or any of such Representatives); or (b) require any filing with, nor any permit, authorization, consent
or approval of, or require any consent of, or registration, declaration or filing with, any Governmental Body, other than (i) any applicable
requirements of the Exchange Act, Nasdaq, and the DGCL, (ii) as required by Antitrust Laws, (iii) as contemplated by the Merger Agreement
(including schedules thereto), and (iv) where the failure to obtain such consents or approvals or to make such filings, would not, individually
or in the aggregate, prevent or materially delay the performance by Parent or Purchaser of their obligations under this Agreement.

 

 SECTION 8.         COVENANTS OF STOCKHOLDER

 

8.1          Stockholder
Information; Disclosure. Stockholder hereby consents to and authorizes the publication and disclosure by Parent, Purchaser and
the Company (including in the Schedule TO, the Schedule 14D-9 or any other publicly filed documents relating to the Merger, the
Offer or the Transactions) of: (a) Stockholder’s identity; (b) Stockholder’s ownership of the Subject Securities; and
(c) the nature of Stockholder’s commitments, arrangements and understandings under this Agreement (including filing this
Agreement as an exhibit to any publicly filed documents relating to the Merger, the Offer or the Transactions), and any other
information that Parent, Purchaser or the Company determines to be necessary in any SEC disclosure document in connection with the
Offer, the Merger or the Transactions. Stockholder further agrees as promptly as practicable to notify Parent, Purchaser and the
Company of any required corrections with respect to any written information supplied by Stockholder specifically for use in any such
disclosure document.

 

    6

     

    

 

8.2          
Further Assurances. From time to time and without additional consideration, Stockholder shall (at Parent’s sole expense)
execute and deliver, or cause to be executed and delivered, such additional transfers, assignments, endorsements, consents and other instruments,
and shall (at Parent’s sole expense) take such further actions, as Parent may reasonably request for the purpose of carrying out
and furthering the intent of this Agreement.

 

8.3          
Stop Transfer Order; Legends. Stockholder hereby agrees that it will not request that the Company register the Transfer of
any certificated or uncertificated interest representing any of the Subject Securities, unless such Transfer is made in compliance with
this Agreement. In furtherance of this Agreement, concurrently herewith, Stockholder shall, and hereby does authorize Parent to direct
the Company or its counsel to, notify the Company’s transfer agent that there is a stop transfer order with respect to all of the
Subject Securities (and that this Agreement places limits on the voting and transfer of such shares). The parties hereto agree that such
stop transfer order shall be removed and shall be of no further force and effect upon the Expiration Date.

 

8.4          
Public Announcement. Stockholder shall not, and shall cause its Representatives not to, directly or indirectly, issue any press
release, public announcement or make any other public statement or communication with respect to the transactions contemplated by this
Agreement or the Merger Agreement without the prior written consent (email sufficient) of Parent, except as may be required by applicable
Law.

 

8.5          
Waiver of Certain Actions. Stockholder hereby agrees not to commence or participate in, and to take all actions necessary to
opt out of any class in any class action with respect to, any claim, derivative or otherwise, against Parent, Purchaser or any of their
respective successors (a) challenging the validity of, or seeking to enjoin or delay the operation of, any provision of this Agreement
or the Merger Agreement (including any claim seeking to enjoin or delay the Expiration Date or the Closing) or (b) alleging a breach of
any duty of the Company Board in connection with the Merger Agreement, this Agreement or the transactions contemplated thereby or hereby.

 

 SECTION 9.         MISCELLANEOUS

 

9.1         
Adjustments. In the event that, between the date of this Agreement and the Effective Time, (a) the outstanding Common Shares
are changed into a different number or class of shares by reason of any stock split, division or subdivision of shares, stock dividend,
reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction, or (b) Stockholder shall
become the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of any additional Common Shares, then the terms of this
Agreement shall apply to the Common Shares held by Stockholder immediately following the effectiveness of the events described in the
aforementioned clause (a) or Stockholder becoming the beneficial owner thereof as described in the aforementioned clause (b), as though,
in either case, they were Subject Securities hereunder. In the event that Stockholder shall become the beneficial owner of any other securities
entitling the holder thereof to vote or give consent with respect to the matters set forth in Section 4 hereof, then the terms
of Section 4 hereof shall apply to such other securities as though they were Subject Securities hereunder.

 

9.2         
Survival of Representations, Warranties and Agreements. All representations, warranties, covenants and agreements in this Agreement,
and all rights and remedies with respect thereto, shall not survive the Expiration Date.

 

    7

     

    

 

9.3         
 Expenses. Except as provided in Sections 4.2 and 8.2 hereof or as otherwise agreed between the parties, all costs and
expenses incurred in connection with the transactions contemplated by this Agreement shall be paid by the party incurring such costs and
expenses.

 

9.4          
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered to Parent
and Purchaser in accordance with Section 10.8 of the Merger Agreement and to each Stockholder at its address set forth below such Stockholder’s
signature hereto (or at such other address for a party as shall be specified by like notice).Severability. Any term or provision
of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or other provision
of this Agreement is invalid, illegal, or incapable of being enforced by any rule of law or public policy, the remaining provisions of
this Agreement will be enforced so as to conform to the original intent of the Parties as closely as possible such that the terms of this
Agreement, the Merger Agreement and the Transactions contemplated therein are fulfilled to the fullest extent possible.

 

9.5         
Entire Agreement; Counterparts. This Agreement and any other documents delivered by the parties in connection herewith constitute
the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties
hereto, with respect to the subject matter hereof and thereof. This Agreement may be executed in several counterparts, each of which shall
be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts
or otherwise) by PDF shall be sufficient to bind the parties hereto to the terms and conditions of this Agreement.

 

9.6         
Assignment; Binding Effect. No party may assign (by merger, operation of law or otherwise) either this Agreement or any of
its rights, interests, or obligations hereunder without the prior written approval of the other parties. Any purported assignment in violation
of this Agreement will be void ab initio.

 

9.7          
Independence of Obligations. The covenants and obligations of Stockholder set forth in this Agreement shall be construed as
independent of any other agreement or arrangement between Stockholder, on the one hand, and the Company, Purchaser or Parent, on the other.
The existence of any claim or cause of action by Stockholder against the Company, Purchaser or Parent shall not constitute a defense to
the enforcement of any of such covenants or obligations against Stockholder.

 

9.8          
Governing Law.

 

(a)                This
Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the Laws that
might otherwise govern under applicable principles of conflicts of laws thereof. Subject to Section 9.9(c), in any action or
proceeding arising out of or relating to this Agreement or the transactions contemplated hereby: (i) each of the parties irrevocably
and unconditionally consents and submits to the exclusive jurisdiction and venue of the Chancery Court of the State of Delaware and
any state appellate court therefrom or, if such court lacks subject matter jurisdiction, the United States District Court sitting in
New Castle County in the State of Delaware, (it being agreed that the consents to jurisdiction and venue set forth in this Section
9.9(a) shall not constitute general consents to service of process in the State of Delaware and shall have no effect for any
purpose except as provided in this paragraph and shall not be deemed to confer rights on any Person other than the parties); and
(ii) each of the parties irrevocably consents to service of process by first class certified mail, return receipt requested, postage
prepaid, to the address at which such party is to receive notice in accordance with Section 9.4. The parties agree that a
final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the
judgment or in any other manner provided by applicable Laws; provided, however, that nothing in the foregoing shall
restrict any party’s rights to seek any post-judgment relief regarding, or any appeal from, such final trial court
judgment.

 

    8

     

    

 

(b)               
The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy will occur
in the event that the parties do not perform their obligations under the provisions of this Agreement in accordance with its specified
terms or otherwise breach such provisions. Subject to the following sentence, the parties acknowledge and agree that (i) the parties shall
be entitled to seek an injunction or injunctions, specific performance, or other equitable relief, to prevent breaches or threatened breaches
of this Agreement and to enforce specifically the terms and provisions hereof in the courts described in Section 9.9(a) without
proof of damages or otherwise, this being in addition to any other remedy to which they are entitled under this Agreement, and (ii) the
right of specific performance is an integral part of the transactions contemplated hereby and without that right, neither the Company
nor Parent would have entered into this Agreement. Each of the parties agrees that it will not oppose the granting of an injunction, specific
performance and other equitable relief on the basis that the other parties have an adequate remedy at law or an award of specific performance
is not an appropriate remedy for any reason at law or equity. The parties acknowledge and agree that any party seeking an injunction or
injunctions to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions of this
Agreement in accordance with this Section 9.9(b) shall not be required to provide any bond or other security in connection with
any such order or injunction.

 

(c)               
EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED
AND DIFFICULT ISSUES, AND THEREFORE SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY
IN ANY LITIGATION ARISING OUT OF, RELATING TO, IN CONNECTION OR TO ENFORCE WITH THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES
THAT (I) NO REPRESENTATIVE, AGENT, OR ATTORNEY OF ANY PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER,
(III) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (IV) EACH OTHER PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

9.9          
Waiver. No failure on the part of any party hereto to exercise any power, right, privilege or remedy under this Agreement,
and no delay on the part of such party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver
of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or remedy. No party shall be deemed to have waived any claim
arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power,
right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such party; and any
such waiver shall not be applicable or have any effect except in the specific instance in which it is given.

 

9.10        Termination. This
Agreement and all rights and obligations of the parties hereunder shall automatically terminate, and no party shall have any rights
or obligations hereunder, and this Agreement shall be revoked and become null and void on, and have no further effect as of the
Expiration Date. Nothing in this Section 9.11 shall relieve any party from any liability for any Willful Breach of this
Agreement occurring prior to the termination of this Agreement and the provisions of this Section 9 (other than Section
9.1) shall survive any termination of this Agreement. For the avoidance of doubt, the representations and warranties herein
shall not survive the termination of this Agreement.

 

    9

     

    

 

9.11        
Directors and Officers. Stockholder signs this Agreement solely in Stockholder’s capacity as a stockholder of the Company,
and not in Stockholder’s (or any Representative of Stockholder’s) capacity as a director, officer or employee of the Company.
Nothing in this Agreement shall be construed to prohibit Stockholder or any of Stockholder’s Representatives who is an officer or
member of the Company Board from taking any action (or failure to act) in his or her capacity as an officer or member of the Company Board
or from taking any action with respect to any Acquisition Proposal solely in their capacity as such an officer or director or in the exercise
of his or her fiduciary duties in his or her capacity as director or officer of the Company, or prevent or be construed to create any
obligation on the part of any director or officer of the Company from taking any action in his or her capacity as such director or officer,
and no action taken solely in any such capacity as an officer or director of the Company shall be deemed to constitute a breach of this
Agreement.

 

9.12       
Construction.

 

(a)               
For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and
the neuter gender shall include masculine and feminine genders.

 

(b)               
The parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall
not be applied in the construction or interpretation of this Agreement.

 

(c)               
As used in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed
to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.” The words “hereof”,
 “herein” and “hereunder” and words of like import used in this Agreement, unless otherwise stated, shall refer
to this Agreement as a whole and not to any particular provision of this Agreement.

 

(d)               
Unless otherwise indicated all references in this Agreement to “Sections” and “Exhibits” are intended to
refer to Sections of this Agreement and Exhibits to this Agreement, as applicable.

 

(e)               
The headings set forth in this Agreement are for convenience of reference purposes only and shall not affect or be deemed to effect
in any way the meaning or interpretation of this Agreement or any term or provision hereof.

 

(f)                
References to “$” refer to United States dollars unless otherwise noted.

 

9.13       
No Ownership Interest. All rights, ownership and economic benefits of and relating to the Subject Securities at a given time
shall remain vested in and belong to Stockholder as of such time, and neither Parent nor Purchaser shall have any authority to exercise
any power or authority to direct Stockholder in the voting of any of the Subject Securities, except as otherwise specifically provided
herein.

 

    10

     

    

 

9.14        
 No Agreement Until Executed. This Agreement shall not be effective unless and until (i) the Merger Agreement is executed by
all parties thereto and (ii) this Agreement is executed by all parties hereto.

 

9.15       
Amendments and Waivers. Any provision of this Agreement may be amended or waived if such amendment or waiver is in writing
and is signed, (i) in the case of an amendment, by each of (x) Parent and the Purchaser, on the one hand, and (y) Stockholder, on the
other hand, or (ii) in the case of a waiver, by each party against whom such waiver is to be effective. No failure or delay by any party
in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof
preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

 

9.16      
Specific Performance. Each of the parties hereto acknowledges and agrees that, in the event of any breach of this Agreement,
each nonbreaching party would be irreparably and immediately harmed and could not be made whole by monetary damages. It is accordingly
agreed that the parties hereto (a) will waive, in any action for specific performance, the defense of adequacy of a remedy at law and
(b) shall be entitled, in addition to any other remedy to which they may be entitled at law or in equity, to compel specific performance
of this Agreement in any action instituted in accordance with Section 9.9 hereof.

 

9.17       
Headings. The Section headings contained in this Agreement are inserted for convenience only and shall not affect in any way
the meaning or interpretation of this Agreement.

 

9.18      
No Presumption. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation
against the party drafting or causing any instrument to be drafted.

 

9.19      
Counterparts. This Agreement may be executed in multiple counterparts, all of which shall together be considered one
and the same agreement.

 

[Remainder of page intentionally left blank]

 

    11

     

    

 

In
Witness Whereof, each of Parent, Purchaser and Stockholder has caused this Tender and Support Agreement to be executed as of the
date first written above. 

 

	 	COLLEGIUM PHARMACEUTICAL, INC. 
	 	 
	 	By:	 
	 	Name: 	 
	 	Title:	 
	 	 
	 	
     

     

    BRISTOL ACQUISITION COMPANY
    INC.

	 	 
	 	By:	 
	 	Name: 	 
	 	Title:	 

 

[Signature Page to Tender and Support Agreement]

 

     

     

    

 

In
Witness Whereof, each of Parent, Purchaser and Stockholder has caused this Tender and Support Agreement to be executed as of the
date first written above. 

 

	 	Stockholder
	 	 
	 	[STOCKHOLDER]
	 	 
	 	By:	 
	 	Name: 
	 	Title:
	 	 
	 	Address:	 
	 	 	 
	 	E-mail:   	 
	 	 	 

 

[Signature Page to Tender and Support Agreement]

 

     

     

    

 

SCHEDULE
A

Subject
Securities, Company RSUs and Company Options

 

	Stockholder 

Name	Company 

Warrants	Common

 Shares	Shares

 Underlying 

Company

 RSUs	Company 

Options	Total 

SharesExhibit 10.2

 

INDEPENDENT CONTRACTOR CONSULTING AGREEMENT

THIS INDEPENDENT CONTRACTOR CONSULTING AGREEMENT (the “Agreement”)
is entered into on the 14th day of February, 2022 and will be effective on the 21st day of February, 2022 (the “Start Date”),
by and between ClearPoint Neuro, Inc., a Delaware corporation (“CLPT”), and Peter Piferi (“Consultant”).

W I T N E S S E T H:

WHEREAS, CLPT is a medical device company focused on creating innovative
platforms for performing the next generation of minimally invasive surgical procedures in the brain;

WHEREAS, CLPT’s ClearPoint® Neuro Intervention System (the “ClearPoint
System”) is designed to enable a range of minimally invasive procedures in the brain;

WHEREAS, Consultant is a highly-skilled professional with expertise in various
aspects of the life sciences and medical device industries, including operations, research and development, patents, procurement, and
manufacturing;

WHEREAS, CLPT desires to engage Consultant, as an independent contractor,
to render certain consulting services to CLPT, and Consultant desires to provide such consulting services to CLPT, on the terms and conditions
set forth herein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:

		1.	Engagement as Consultant. CLPT hereby engages Consultant
to render consulting services to CLPT, and Consultant hereby accepts such engagement to render such consulting services to CLPT, upon
the terms and conditions set forth herein.

		2.	Consulting Services. Consultant will provide CLPT the consulting
services set forth on Exhibit A attached hereto (the “Consulting Services”), as requested by CLPT and agreed to by the parties
from time to time. Consultant will (a) devote such time, energy and skill as may be necessary to diligently perform the Consulting Services,
and (b) timely prepare and forward to CLPT all deliverables related to the Consulting Services as may be reasonably requested by CLPT.
No Consulting Services will be provided by Consultant prior to execution of this Agreement. Consultant is a non-exclusive provider of
services to CLPT, and CLPT has the sole discretion to decide whether to use Consultant’s services in any given situation. Consultant
will have the right to control the performance of the Consulting Services, as the result of the work is the primary factor bargained for
in this consulting relationship, and not the manner, method or means by which the result is obtained.

		3.	Compensation. For Consulting provided to CLPT hereunder,
CLPT will pay Consultant at a rate of Ten Thousand Dollars ($10,000.00) per month, in arrears. Payment for any partial months shall be
prorated on a calendar day basis.

		4.	Expenses. To the extent CLPT requests Consultant to provide
Consulting Services at a location away from the metropolitan area where Consultant resides, CLPT will reimburse Consultant for reasonable
travel and living expenses incurred by Consultant in providing such Consulting

    1 

     

    

Services. Otherwise, CLPT will not be responsible for any out-of-pocket
expenses incurred by Consultant in connection with the performance of Consulting Services hereunder unless such expenses are agreed to
in advance by CLPT in writing. In any event, (a) CLPT's obligation to reimburse expenses pursuant to this Section 4 is subject to Consultant’s
presentation to CLPT of a voucher or other documentation reasonably satisfactory to CLPT indicating the amount and purpose of the expenses
incurred by Consultant, and (b) all expenses for which Consultant requests reimbursement must be consistent with all applicable laws,
rules and regulations as well as CLPT's Interactions with Healthcare Professionals Policy.

		5.	Term.

		a.	The initial term of this Agreement will be from the Start Date until April 22, 2022 (the “Initial Term”). The Parties
may elect to extend the term on a month-by-month basis, for up to two (2) years from the Start Date. Unless renewed by mutual agreement
between the Parties (which can be in the form of an email acknowledgment between CLPT’s CEO or CFO and Consultant), this Agreement
will automatically expire on April 22, 2022.

		b.	Notwithstanding the foregoing, either party may terminate this Agreement on ten (10) days’ written notice to the other party
in the event of a breach of any material provision of this Agreement by such other party if, during such 10-day period, the breaching
party fails to cure such breach; provided; however, that CLPT may terminate this Agreement immediately upon written notice to Consultant
(i) in the event of Consultant’s breach of Sections 6, Section 7, or (ii) in the event any of the circumstances described in Section
8 occurs.

		c.	The provisions of Sections 6, 9, 11, 12, 13, and 15 of this Agreement will survive any termination of this Agreement.

		6.	Confidential Information

		a.	Company Property. In connection with the performance of Consulting Services, Consultant
may receive information, analyses, compilations, plans, designs, concepts, devices, research, studies and other materials relating to
CLPT’s existing or potential business that are not generally available to the public (“Confidential Information”). Without
CLPT’s prior written consent (which consent may be withheld in CLPT’s sole and absolute discretion), Consultant will not (a)
in any way disclose any of the Confidential Information to any third party, or (b) in any way use any of the Confidential Information
other than in the performance of the Consulting Services for CLPT's exclusive benefit. Without in any way limiting the generality of the
foregoing, in no event may Consultant include any Confidential Information in any application for patent or other proprietary protection
filed by or on behalf of Consultant in any country or jurisdiction. Consultant will take all reasonable steps to safeguard the Confidential
Information in order to prevent unauthorized disclosure or use thereof. All Confidential Information coming into Consultant's possession,
regardless of the form, will remain CLPT's exclusive property. Consultant will return to CLPT all CLPT property obtained during the course
of this Agreement when this Agreement terminates or at such earlier time as requested by CLPT.

		b.	Developed Works. Consultant will promptly disclose to CLPT, in confidence and (if requested
by CLPT) in writing, any discoveries, inventions, data, information, procedures, conclusions and other results conceived, created, developed,
made or

    2 

     

    

prepared by Consultant in connection with or as a result of the performance
of Consultant’s Services or otherwise based on any Confidential Information received by Consultant (“Developed Works”).
CLPT will be the sole owner of all Developed Works and all intellectual property rights with respect thereto throughout the world. Consultant
hereby irrevocably assigns to CLPT all right, title and interest of Consultant in and to any and all Developed Works and all intellectual
property rights with respect thereto, whether or not patentable, copyrightable or protectable as trade secrets. Consultant acknowledges
that any Developed Work which is an original work of authorship and which is copyrightable is a “work made for hire,” as that
term is defined in the United States Copyright Act. In addition to the foregoing assignment of Developed Works (and all intellectual property
rights with respect thereto) to CLPT, Consultant hereby irrevocably assigns to CLPT any and all “moral rights” that Consultant
may have in or with respect to any Developed Work, and Consultant forever waives and agrees not to assert any and all “moral rights”
he may have in or with respect to any Developed Work. All Developed Works will constitute Confidential Information subject to the provisions
of Section 6(a) above. Consultant agrees to assist CLPT in obtaining and, from time to time, enforcing United States and foreign intellectual
property rights relating to Developed Works assigned hereunder to CLPT. To that end, Consultant will execute, verify and deliver such
documents and perform such other acts as CLPT may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining
and enforcing such intellectual property rights and the assignment thereof. In addition, Consultant will execute, verify and deliver assignments
of such intellectual property rights to CLPT or its designee.

		7.	Consultant Representations and Covenants. Consultant represents, warrants and, for the
term of this Agreement, covenants to CLPT that:

		a.	Consultant has the requisite expertise, ability, and legal right to render the Consulting Services to CLPT pursuant to this Agreement,
and Consultant will perform the Consulting Services in an efficient manner and in accordance with the terms of this Agreement;

		b.	Consultant's execution and delivery of this Agreement, and Consultant’s performance under this Agreement, do not and will not
(i) breach or otherwise conflict with any obligations binding on Consultant or to which Consultant is or becomes subject, or (ii) require
the consent of any third party that has not already been obtained as of the Effective Date;

		c.	Consultant has not entered into, and will not enter into, any agreement, either written or oral, in conflict with this Agreement;

		d.	Consultant does not have any relationship with a third party, including a competitor of CLPT, which would present a conflict of interest
with Consultant’s performance of the Consulting Services, or which would prevent Consultant from carrying out the provisions of
this Agreement, and Consultant will not enter into any such relationship during the term of this Agreement;

		e.	Consultant will comply with all applicable laws, rules and regulations in connection with his performance of the Consulting Services
hereunder and will comply with all CLPT policies otherwise applicable to employee conduct, including, but not limited to, CLPT's Interactions
with Healthcare Professionals Policy (which Consultant acknowledges having received);

    3 

     

    

		f.	Consultant will not publish, nor submit for publication, any confidential or proprietary work resulting
from the Consulting Services provided hereunder without CLPT’s prior written consent;

		g.	Consultant will not, without the prior written consent of CLPT, take any action that reasonably could
result in any person other than CLPT having a claim to an ownership interest in any Developed Works;

		h.	Consultant will not include any confidential, trade secret or other proprietary information of any
third party, or any “protected health information” (within the meaning of the HIPAA Privacy Rule), in any information disclosed
to CLPT;

		i.	Consultant is not currently, and has never been, (i) a person who has been debarred, excluded or suspended
from (A) participating in any federal health care program, (B) participating in any federal contracting by the U.S. General Services Administration
or (C) submitting or assisting in the submission of any abbreviated drug application with the U.S. Food and Drug Administration (in either
case, “Debarment” or “Debarred”, as applicable), or (ii) an employee, partner, stockholder or member of a Debarred
person;

		j.	Consultant has never been criminally convicted or found civilly liable for violating any federal,
state or local law, including, without limitation, the federal health care program anti-kickback statute (42 U.S.C §1320a-7b); and

		k.	Consultant is not currently, and has never been, designated as a “Specially Designated National”
or “Blocked Person” by the Office of Foreign Asset Control of the U.S. Department of the Treasury.

		8.	Required Notices. Consultant will immediately provide written notice to CLPT if:

		a.	Consultant becomes a Debarred person or receives notice of action or threat of action with respect
to his Debarment;

		b.	Consultant is criminally convicted or found civilly liable for violating any federal, state or local
law, including, without limitation, the federal health care program anti-kickback statute (42 U.S.C.);

		c.	Consultant becomes designated as a “Specially Designated National” or “Blocked Person”
by the Office of Foreign Asset Control of the U.S. Depa1tment of the Treasury.

		d.	Consultant accepts employment with a competitor of CLPT which could or does present an actual or perceived
conflict of interest with Consultant’s performance of Consulting Services; or

		e.	Consultant performs consultative services to a competitor of CLPT, such that the nature of Consultant’s
work for the competitor is similar to, or the same as, the Consulting Services Consultant is performing on behalf of CLPT which could
or does present an actual or perceived conflict of interest with Consultant’s performance of Consulting Services.

    4 

     

    

		9.	Indemnification. Consultant will indemnify CLPT and hold CLPT harmless from and against
any and all claims, demands, losses, costs, expenses, obligations, liabilities, damages, recoveries and deficiencies (including, without
limitation, interest, penalties, court costs and attorneys’ fees) (collectively, “Losses”) which arise out of or relate
to (a) any breach or alleged breach of any of Consultant's representations and warranties contained herein, or (b) the breach or alleged
breach by Consultant of any covenant or agreement to be performed hereunder.

		10.	Intentionally Omitted.

		11.	Independent Contractor. Consultant will be an independent contractor of CLPT. Consultant
will not be an agent, employee or representative of CLPT, and nothing herein should be construed to constitute Consultant as such. Consultant
will not, under any circumstances, look to CLPT as his employer, or as a partner, agent or principal, and Consultant will have no right,
power or authority to create any obligation, express or implied, on behalf of CLPT. As an independent contractor, Consultant will not
be entitled to any benefits accorded to CLPT’s employees (including, without limitation, workers’ compensation, health insurance,
disability insurance, vacation or sick pay), and CLPT will not be responsible for withholding from the compensation payable to Consultant
any amounts for federal, state or local income taxes, social security or state disability or unemployment insurance. Consultant will have
the entire responsibility to discharge any and all of his obligations relating to taxes, unemployment compensation or insurance, social
security, workers’ compensation, disability pensions and tax withholdings (the “Tax Obligations”). Without limiting
the generality of Section 9 above, Consultant hereby agrees to indemnify CLPT and hold CLPT harmless for any and all Losses incurred or
suffered by CLPT which arise out of Consultant's failure to properly discharge his Tax Obligations.

		12.	Entire Agreement. This Agreement constitutes the entire agreement between the parties
with respect to Consultant’s Consulting Services on behalf of CLPT, and will supersede all previous negotiations, commitments, and
writings with respect to Consultant’s Consulting Services on behalf of CLPT.

		13.	Amendment. No amendment, modification or supplement of any provision of this Agreement
will be valid or effective unless made in writing and signed by each party.

		14.	Assignment. This Agreement will be binding upon and will inure to the benefit of CLPT
and Consultant and their respective successors and assigns; provided, however, that Consultant may not assign this Agreement or delegate
any duties and obligations hereunder.

		15.	Notices. Any notice required under this Agreement must be in writing, must be addressed
as provided below and will be deemed delivered (a) three business days after deposit in the United States mail, postage prepaid and registered
or certified, return receipt requested, (b) one business day after sent by nationally recognized overnight receipted courier service with
next day delivery specified, or (c) when actually received by the party to whom such notice is required to be given, if such notice is
delivered via electronic mail or any similar method not identified in the preceding clauses (a) and (b):

		·	If to CLPT, CLPT's address as set forth on the signature page of this Agreement;

		·	If to Consultant, Consultant's address as set forth on the signature page of this Agreement;

		·	and in any case at such other address as a party may specify by written notice in accordance with this section. All periods of notice
will be measured from the date of deemed delivery as provided in this section.

    5 

     

    

		16.	Severability. Whenever possible, each provision of this Agreement will be interpreted
in a manner to be effective, valid and enforceable. If, however, any provision of this Agreement is held to be illegal, invalid or unenforceable
under any present or future law, then such provision will be ineffective only to the extent of such prohibition or invalidity, without
invalidating or affecting in any manner whatsoever the remainder of such provision or the remaining provisions of this Agreement. Furthermore,
there will be added automatically as a part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable
provision as may be possible and still have such similar provision be construed and enforced as legal, valid, and enforceable.

		17.	Descriptive Headings. The descriptive headings of this Agreement are for convenience
only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement.

		18.	Waiver of Compliance. The failure of either party to comply with any obligation, covenant,
agreement or condition under this Agreement may be waived by the party entitled to the benefit thereof only by a written instrument signed
by the party on granting such waiver, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement
or condition will not operate as a waiver of, or estoppel with respect to, any subsequent or other failure.

		19.	Counterparts. This Agreement may be executed in any number of counterparts, each of
which need not contain the signature of more than one party but all such counterparts taken together will constitute one and the same
agreement. In the event that any signature is delivered by facsimile transmission, or by e-mail delivery of a ".pdf' format data
file, such signature will create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile or ".pdf ' signature page was an original thereof.

		20.	Construction. All plural nouns and pronouns will be deemed to include the singular case
thereof where the context requires, and vice versa. All pronouns will be gender neutral unless the context otherwise requires. Any reference
to any federal, state, local, or foreign statute or law will be deemed also to refer to all rules and regulations promulgated thereunder,
unless the context otherwise requires. The word "including" will mean including without limitation.

    6 

     

    

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
Effective Date.

 

 

CLEARPOINT NEURO, INC.

 

By: /s/ Danilo D’Alessandro           

 

Name: Danilo D’Alessandro 

Title: Chief Financial Officer

 

 

Address for Notice:

 

ClearPoint Neuro, Inc.

120 S. Sierra Ave., Suite 100 

Solana Beach, CA 92075 

Attention:
General Counsel

 

CONSULTANT:

 

 

/s/ Peter G. Piferi                        

Peter G. Piferi

 

 

Address for Notice: 

6026 E. Teton Ave. 

Orange, CA 92867

 

    7 

     

    

EXHIBIT A

Consultant will provide consulting services related to transitioning
Consultant’s job functions and responsibilities to other senior executives of the CLPT, and providing other assistance as may be
reasonably requested by CLPT.

For the term requested by the CLPT, Consultant will serve as
CLPT’s Interim Head of Regulatory.

Consultant will be provided access to all CLPT systems and applications
to provide the Consulting Services.

 

    8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]